BioSphere Medical Names Willard W. Hennemann, Ph.D. Vice President, New Product and Business Development.

ROCKLAND, Mass. -- BioSphere Medical, Inc. (NASDAQ: BSMD) ("BioSphere"), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today announced that Willard (Bill) W. Hennemann, Ph.D. has been named to the newly created position of Vice President, New Product and Business Development. Dr. Hennemann brings more than 20 years of worldwide experience in the research, development, and marketing of interventional vascular medical devices. He will report to Richard Faleschini, BioSphere's President and Chief Executive Officer.

Dr. Hennemann spent six years as Vice President of Research and Development/Interventional Vascular at CryoCath Technologies, a world leader in catheter-based products for the cryotherapeutic treatment of cardiovascular disease. While managing a team of 40 professionals at CryoCath, he directed parallel R&D programs covering a variety of medical specialties and successfully developed and introduced new technologies in Europe, Canada, and the United States. Prior to this, Dr. Hennemann served as Director of Marketing and Product Development at Intervascular (a division of Datascope) and spent two years as Director of Marketing/International Clinical Studies, Global Stent Business Unit for Medtronic, Inc. At Medtronic, Dr. Hennemann's team launched new stent platforms and line extensions in the United States and Europe, including the world's first CE-marked heparin-coated stent. Prior to Medtronic, Dr. Hennemann assumed roles of increasing responsibility over a 12-year period with Cordis Corporation, a pioneer in developing innovative diagnostic and therapeutic devices and products for interventional vascular medicine.

Following CryoCath and before joining BioSphere Medical, Dr. Hennemann served as Vice President, Intravascular Systems/Marketing for Medeikon Corporation, a privately held developer of proprietary disposable technologies to diagnose and treat cardiovascular disease. In this role, he was responsible for overseeing the development of disposable catheters and guidwewires, as well as strategic and tactical marketing.

Dr. Hennemann received his B.S. from the University of Maryland and his Ph.D. from the University of Florida, where he was a Postdoctoral Fellow from 1982-1984. He has been issued five U.S. patents related to interventional medical devices and has five patents pending. Dr. Hennemann has authored or coauthored 18 articles and four abstracts in peer-reviewed scientific journals.

Richard Faleschini, President and Chief Executive Officer of BioSphere Medical, commented, "Bill is a capable veteran of the medical device industry with a broad range of experiences and accomplishments that we believe are relevant to BioSphere, including the assessment and determination of customer requirements for new products, development and launch of new products, and business growth through industry partnerships and business and corporate development activities. Bill's primary responsibilities will be to refine and seek to execute our new product development plan and to lead our recently announced strategic collaboration with the Applied BioSciences group at DuPont, as well as lead our inbound and outbound business development activities. We welcome Bill to our management team."

About BioSphere Medical, Inc.

BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to develop and commercialize minimally invasive diagnostic and therapeutic applications based upon its pioneering proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties that are designed for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure, as well as in a number of other new and established medical treatments.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For a discussion of important risks and uncertainties which could cause actual results to differ from those contained in such forward-looking statements, see "Risk Factors" in BioSphere's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date of this press release, and the Company disclaims any obligation to update these forward-looking statements as a result of changed events, circumstances or otherwise.